

December 7, 2018

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: Intimation about Distribution Agreement between AstraZeneca Pharma India Limited (“Company”) and Abbott Healthcare Private Limited (“Abbott”) for innovative type 2 diabetes medicine, Dapagliflozin.

We wish to inform that the Company and Abbott have today entered into a Distribution Agreement for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is Company’s leading diabetes medicine.


Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name **GLEDEPA**. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name **GLEDEPA MET**.

The Company will continue to promote and distribute dapagliflozin under the brand name **Forxiga** and combination of dapagliflozin with metformin under the brand name **Xigduo**.

We request you to kindly take this intimation on records.

Thanking you,

For AstraZeneca Pharma India Limited


Pratap Rudra

Company Secretary & Legal Counsel

